TREAT-AD’s mission is to address the urgent need for therapies to effectively treat or prevent Alzheimer’s disease
Two Centers, One Mission
The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD), and 2) initiate early stage drug discovery campaigns against the enabled targets. Central to this initiative is the open-access, rapid dissemination of data, methods, and computational and experimental tools generated by the Centers to all qualified researchers for their use in advancing AD drug discovery and AD disease biology.
Sage is part of the Emory-Sage-SGC center. Our mission is to diversify the portfolio of drug targets in Alzheimer’s disease (AD). Learn more about TREAT-AD and our collaborators at treatad.org.
More Scientific Coordination Projects
Multi-Consortia Coordinating (MC2) Center
Sage Bionetworks leads the Multi-Consortia Coordinating (MC2) Center for six research consortia from the NIH/NCI Division of Cancer Biology. The MC2 Center aims to catalyze...Learn More
The Gray Foundation
The Gray Foundation "Team Science" philanthropic initiative funds a network of researchers to study new approaches for the early detection, diagnosis, and therapy of BRCA-related...Learn More
The First 1000 Days 1kD
The 1kD program is an international effort to better understand executive development in toddlers up to 1000 days old.Learn More